Study design
This prospective observational study focused on the immunogenicity,
safety, and efficacy of the mRNA vaccine BNT162b2. The study followed
STROBE recommendations (STrengthening the Reporting of OBservational
studies in Epidemiology) . Patients received two standard doses (0.3
mL/30 µg mRNA) intramuscularly within the recommended 3-week interval
and were followed up for 6 months post-vaccination. The follow-up period
was divided into six consecutive visits. The study design is illustrated
in Fig 1. This study was conducted from March 2021 to November 2021.